^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

FPI-1434

i
Other names: FPI-1434, [225Ac]-FPI-1434 Injection, FPX01
Associations
Trials
Company:
AstraZeneca
Drug class:
IGF-1R inhibitor, Alpha radiation emitter
Related drugs:
Associations
Trials
1year
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection (clinicaltrials.gov)
P1/2, N=253, Recruiting, Fusion Pharmaceuticals Inc. | Trial primary completion date: Jun 2023 --> Jun 2024
Trial primary completion date • Metastases
|
IGF1 (Insulin-like growth factor 1) • IGFBP3 (Insulin-like growth factor binding protein 3)
|
HER-2 negative
|
FPI-1434
almost2years
Current and future targeted alpha particle therapies for osteosarcoma: Radium-223, actinium-225, and thorium-227. (PubMed, Front Med (Lausanne))
This review will detail experience using the alpha emitter radium-223 (Ra, tradename Xofigo), that targets bone formation, in osteosarcoma, specifically related to patient selection, use of gemcitabine for radio-sensitization, and using denosumab to increasing the osteoblastic phenotype of these cancers. A case of an inoperable left upper lobe vertebral-paraspinal-mediastinal osteoblastic lesion treated successfully with Ra combined with gemcitabine is described. Because not all areas of osteosarcoma lesions are osteoblastic, but nearly all osteosarcoma cells overexpress IGF1R, and some subsets expressing Her-2, the anti-IGF1R antibody FPI-1434 linked to actinium-225 (Ac) or the Her-2 antibody linked to thorium-227 (Th) may become other means to provide targeted alpha particle therapy against osteosarcoma (NCT03746431 and NCT04147819).
Review • Journal
|
IGF1R (Insulin-like growth factor 1 receptor)
|
HER-2 expression • IGF1R expression • IGF1R overexpression
|
gemcitabine • Prolia (denosumab) • Xofigo (radium Ra-223 dichloride) • FPI-1434
2years
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection (clinicaltrials.gov)
P1/2, N=227, Recruiting, Fusion Pharmaceuticals Inc. | Trial primary completion date: Jun 2022 --> Jun 2023
Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • IGF1 (Insulin-like growth factor 1) • IGFBP3 (Insulin-like growth factor binding protein 3)
|
HER-2 negative
|
FPI-1434
almost3years
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection (clinicaltrials.gov)
P1/2, N=227, Recruiting, Fusion Pharmaceuticals Inc. | Phase classification: P1 --> P1/2 | N=38 --> 227 | Trial completion date: Dec 2022 --> Jun 2026
Phase classification • Enrollment change • Trial completion date
|
IGF1 (Insulin-like growth factor 1) • IGFBP3 (Insulin-like growth factor binding protein 3)
|
FPI-1434
4years
A Phase 1 Study of [225Ac]-FPI-1434 Injection (clinicaltrials.gov)
P1, N=38, Recruiting, Fusion Pharmaceuticals Inc. | Trial completion date: Jan 2021 --> Dec 2022 | Trial primary completion date: Jul 2020 --> Apr 2022
Clinical • Trial completion date • Trial primary completion date
|
IGF1 (Insulin-like growth factor 1) • IGFBP3 (Insulin-like growth factor binding protein 3)
|
FPI-1434